...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer
【24h】

Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer

机译：有症状的心脏毒性是由剂量和患者因素预测的，而不是食管癌放化疗后通过18F-FDG PET测定心肌活性的变化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To determine factors associated with symptomatic cardiac toxicity in patients with esophageal cancer treated with chemoradiotherapy. Material and methods: We retrospectively evaluated 102 patients treated with chemoradiotherapy for locally advanced esophageal cancer. Our primary endpoint was symptomatic cardiac toxicity. Radiation dosimetry, patient demographic factors, and myocardial changes seen on 18F-FDG PET were correlated with subsequent cardiac toxicity. Cardiac toxicity measured by RTOG and CTCAE v3.0 criteria was identified by chart review. Results: During the follow up period, 12 patients were identified with treatment related cardiac toxicity, 6 of which were symptomatic. The mean heart V20 (79.7% vs. 67.2%, p = 0.05), V30 (75.8% vs. 61.9%, p = 0.04), and V40 (69.2% vs. 53.8%, p = 0.03) were significantly higher in patients with symptomatic cardiac toxicity than those without. We found the threshold for symptomatic cardiac toxicity to be a V20, V30 and V40 above 70%, 65% and 60%, respectively. There was no correlation between change myocardial SUV on PET and cardiac toxicity, however, a greater proportion of women suffered symptomatic cardiac toxicity compared to men (p = 0.005). Conclusions: A correlation did not exist between percent change in myocardial SUV and cardiac toxicity. Patients with symptomatic cardiac toxicity received significantly greater mean V20, 30 and 40 values to the heart compared to asymptomatic patients. These data need validation in a larger independent data set.
机译：目的：确定经放化疗治疗的食管癌患者的症状性心脏毒性相关因素。材料和方法：我们回顾性评估了102例接受放化疗的局部晚期食管癌患者。我们的主要终点是症状性心脏毒性。在18F-FDG PET上观察到的辐射剂量，患者人口统计学因素和心肌变化与随后的心脏毒性相关。通过RTOG和CTCAE v3.0标准测得的心脏毒性通过图表审查确定。结果：在随访期间，确定了12例与治疗有关的心脏毒性反应的患者，其中6例是有症状的。患者的平均心脏V20（79.7％vs. 67.2％，p = 0.05），V30（75.8％vs.61.9％，p = 0.04）和V40（69.2％vs.53.8％，p = 0.03）显着更高具有症状性心脏毒性的患者比无症状者。我们发现症状性心脏毒性的阈值分别是V20，V30和V40分别高于70％，65％和60％。 PET引起的心肌SUV改变与心脏毒性之间无相关性，但是与男性相比，有症状的女性心脏心脏毒性更大（p = 0.005）。结论：心肌SUV百分比变化与心脏毒性之间不存在相关性。与无症状患者相比，有症状心脏毒性患者的心脏平均V20、30和40值更高。这些数据需要在更大的独立数据集中进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号